Symbols / DWTX $2.04 -3.32% Dogwood Therapeutics, Inc.
DWTX Chart
About
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2020 and is based in Alpharetta, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 67.92M |
| Enterprise Value | 104.45M | Income | -35.51M | Sales | — |
| Book/sh | 2.52 | Cash/sh | 0.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -0.32 | PEG | — |
| P/S | — | P/B | 0.81 | P/C | — |
| EV/EBITDA | -3.73 | EV/Sales | — | Quick Ratio | 2.13 |
| Current Ratio | 2.76 | Debt/Eq | 0.22 | LT Debt/Eq | — |
| EPS (ttm) | -7.13 | EPS next Y | -6.37 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -18.95% |
| ROE | -49.23% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 29.73M |
| Shs Float | 4.80M | Short Float | 0.43% | Short Ratio | 1.39 |
| Short Interest | — | 52W High | 9.50 | 52W Low | 1.77 |
| Beta | 2.07 | Avg Volume | 58.27K | Volume | 96.92K |
| Target Price | $14.00 | Recom | Strong_buy | Prev Close | $2.11 |
| Price | $2.04 | Change | -3.32% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2026-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-30 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-23 | up | HC Wainwright & Co. | Neutral → Buy | $10 |
- Dogwood Therapeutics (Nasdaq: DWTX) holders back major warrant exercise - Stock Titan hu, 12 Mar 2026 07
- Dogwood Therapeutics (DWTX) price target decreased by 26.32% to 14.28 - MSN Wed, 01 Apr 2026 08
- DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence - Stocktwits Mon, 22 Dec 2025 08
- HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat Mon, 23 Mar 2026 07
- DWTX: Financing Secures Funding Through Phase 2b Data Readout - Smartkarma Mon, 02 Feb 2026 08
- If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan Sun, 22 Mar 2026 21
- DWTX Jumps on High Trading Volume, Not Due to News - Bitget Fri, 20 Mar 2026 07
- Dogwood Therapeutics, Inc. Announces Financing of up to - GlobeNewswire Mon, 12 Jan 2026 08
- Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% - Time to Buy? - MarketBeat Sat, 14 Mar 2026 07
- Dogwood Therapeutics extends cash runway as pain drug trial advances - Stock Titan Wed, 18 Mar 2026 07
- Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1% - MarketBeat Mon, 16 Mar 2026 07
- Dogwood Therapeutics (NASDAQ: DWTX) details non-opioid pain pipeline in Q1 2026 update - Stock Titan hu, 26 Mar 2026 07
- Cancer pain drug Halneuron shows early promise as major trial hits halfway - Stock Titan Mon, 02 Feb 2026 08
- Early trial hints at new option for chemo-related nerve pain sufferers - Stock Titan Mon, 22 Dec 2025 08
- Dogwood Therapeutics (Nasdaq: DWTX) ramps R&D and extends cash runway - Stock Titan Wed, 18 Mar 2026 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
27.97
+128.74%
|
12.23
+124.48%
|
5.45
-55.77%
|
12.32
|
| Research And Development |
|
21.87
+519.28%
|
3.53
+104.33%
|
1.73
-78.59%
|
8.07
|
| Selling General And Administration |
|
6.10
-29.83%
|
8.70
+133.85%
|
3.72
-12.41%
|
4.25
|
| General And Administrative Expense |
|
6.10
-29.83%
|
8.70
+133.85%
|
3.72
-12.41%
|
4.25
|
| Other Gand A |
|
6.10
-29.83%
|
8.70
+133.85%
|
3.72
-12.41%
|
4.25
|
| Total Expenses |
|
27.97
+128.74%
|
12.23
+124.48%
|
5.45
-55.77%
|
12.32
|
| Operating Income |
|
-27.97
-128.74%
|
-12.23
-124.48%
|
-5.45
+55.77%
|
-12.32
|
| Total Operating Income As Reported |
|
-27.97
-128.74%
|
-12.23
-124.48%
|
-5.45
+55.77%
|
-12.32
|
| EBITDA |
|
-27.97
-128.95%
|
-12.22
-124.26%
|
-5.45
+55.77%
|
-12.32
|
| Normalized EBITDA |
|
-21.80
-78.93%
|
-12.18
-123.69%
|
-5.45
+55.77%
|
-12.32
|
| Reconciled Depreciation |
|
0.00
-83.06%
|
0.01
|
0.00
|
—
|
| EBIT |
|
-27.97
-128.74%
|
-12.23
-124.48%
|
-5.45
+55.77%
|
-12.32
|
| Total Unusual Items |
|
-6.16
-19923.93%
|
-0.03
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-6.16
-19923.93%
|
-0.03
|
—
|
—
|
| Special Income Charges |
|
-6.14
|
0.00
|
—
|
—
|
| Other Special Charges |
|
6.13
|
—
|
—
|
—
|
| Net Income |
|
-34.26
-177.39%
|
-12.35
-133.19%
|
-5.30
+56.76%
|
-12.25
|
| Pretax Income |
|
-34.04
-175.59%
|
-12.35
-133.20%
|
-5.30
+56.76%
|
-12.25
|
| Net Non Operating Interest Income Expense |
|
0.10
+205.15%
|
-0.09
-161.09%
|
0.15
+123.64%
|
0.07
|
| Interest Expense Non Operating |
|
—
|
0.09
|
—
|
—
|
| Net Interest Income |
|
0.10
+205.15%
|
-0.09
-161.09%
|
0.15
+123.64%
|
0.07
|
| Interest Expense |
|
—
|
0.09
|
—
|
—
|
| Interest Income Non Operating |
|
—
|
—
|
0.15
+123.64%
|
0.07
|
| Interest Income |
|
—
|
—
|
0.15
+123.64%
|
0.07
|
| Other Income Expense |
|
-6.16
-19923.93%
|
-0.03
|
—
|
—
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
-0.03
+9.33%
|
-0.03
|
—
|
—
|
| Tax Provision |
|
0.22
+44055.47%
|
-0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+512095.12%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-1.29
-103246434.59%
|
-0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-34.26
-177.39%
|
-12.35
-133.19%
|
-5.30
+56.76%
|
-12.25
|
| Net Income From Continuing Operation Net Minority Interest |
|
-34.26
-177.39%
|
-12.35
-133.19%
|
-5.30
+56.76%
|
-12.25
|
| Net Income From Continuing And Discontinued Operation |
|
-34.26
-177.39%
|
-12.35
-133.19%
|
-5.30
+56.76%
|
-12.25
|
| Net Income Continuous Operations |
|
-34.26
-177.39%
|
-12.35
-133.19%
|
-5.30
+56.76%
|
-12.25
|
| Normalized Income |
|
-29.39
-138.55%
|
-12.32
-132.61%
|
-5.30
+56.76%
|
-12.25
|
| Net Income Common Stockholders |
|
-35.51
-176.08%
|
-12.86
-142.90%
|
-5.30
+56.76%
|
-12.25
|
| Diluted EPS |
|
—
|
-12.52
-78.86%
|
-7.00
+74.77%
|
-27.75
|
| Basic EPS |
|
—
|
-12.52
-78.86%
|
-7.00
+74.77%
|
-27.75
|
| Basic Average Shares |
|
—
|
1.03
+36.84%
|
0.75
+69.62%
|
0.44
|
| Diluted Average Shares |
|
—
|
1.03
+36.84%
|
0.75
+69.62%
|
0.44
|
| Diluted NI Availto Com Stockholders |
|
-35.51
-176.08%
|
-12.86
-142.90%
|
-5.30
+56.76%
|
-12.25
|
| Gain On Sale Of PPE |
|
-0.00
|
0.00
|
—
|
—
|
| Preferred Stock Dividends |
|
1.26
+144.44%
|
0.51
|
—
|
—
|
| Total Other Finance Cost |
|
-0.10
-205.15%
|
0.09
|
—
|
-0.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
90.17
-4.39%
|
94.31
+2164.06%
|
4.17
|
| Current Assets |
|
8.43
-49.04%
|
16.54
+297.18%
|
4.17
|
| Cash Cash Equivalents And Short Term Investments |
|
6.52
-56.06%
|
14.85
+347.64%
|
3.32
|
| Cash And Cash Equivalents |
|
6.52
-56.06%
|
14.85
+347.64%
|
3.32
|
| Cash Financial |
|
6.52
-56.06%
|
14.85
+347.64%
|
3.32
|
| Prepaid Assets |
|
1.90
+13.97%
|
1.67
+97.47%
|
0.84
|
| Other Current Assets |
|
0.00
-82.59%
|
0.03
+686.91%
|
0.00
|
| Total Non Current Assets |
|
81.74
+5.11%
|
77.76
|
0.00
|
| Net PPE |
|
0.19
-19.04%
|
0.24
|
0.00
|
| Gross PPE |
|
0.19
-19.57%
|
0.24
|
0.00
|
| Accumulated Depreciation |
|
0.00
+100.00%
|
-0.00
|
—
|
| Machinery Furniture Equipment |
|
0.01
-30.64%
|
0.02
|
—
|
| Construction In Progress |
|
0.02
+4.99%
|
0.02
|
—
|
| Other Properties |
|
0.16
-20.74%
|
0.21
|
—
|
| Goodwill And Other Intangible Assets |
|
81.39
+4.98%
|
77.52
|
0.00
|
| Goodwill |
|
12.40
+4.98%
|
11.81
|
0.00
|
| Other Intangible Assets |
|
68.99
+4.98%
|
65.71
|
—
|
| Non Current Deferred Assets |
|
0.16
|
0.00
|
—
|
| Non Current Prepaid Assets |
|
—
|
0.02
|
0.00
|
| Total Liabilities Net Minority Interest |
|
15.27
-49.13%
|
30.03
+8274.67%
|
0.36
|
| Current Liabilities |
|
3.06
-3.69%
|
3.18
+785.89%
|
0.36
|
| Payables And Accrued Expenses |
|
2.26
-5.53%
|
2.39
+566.40%
|
0.36
|
| Payables |
|
0.76
-38.23%
|
1.23
+1000.68%
|
0.11
|
| Accounts Payable |
|
0.76
-38.23%
|
1.23
+1000.68%
|
0.11
|
| Current Accrued Expenses |
|
1.50
+29.27%
|
1.16
+369.34%
|
0.25
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.75
+1.06%
|
0.74
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
0.06
+14.38%
|
0.05
|
—
|
| Current Capital Lease Obligation |
|
0.06
+14.38%
|
0.05
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
12.22
-54.51%
|
26.85
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.11
-99.32%
|
15.54
|
0.00
|
| Long Term Debt |
|
—
|
15.38
|
—
|
| Long Term Capital Lease Obligation |
|
0.11
-31.72%
|
0.15
|
0.00
|
| Non Current Deferred Liabilities |
|
12.11
+7.02%
|
11.31
|
0.00
|
| Non Current Deferred Taxes Liabilities |
|
12.11
+7.02%
|
11.31
|
0.00
|
| Stockholders Equity |
|
74.90
+16.51%
|
64.28
+1588.54%
|
3.81
|
| Common Stock Equity |
|
74.90
+839.77%
|
-10.12
-365.95%
|
3.81
|
| Capital Stock |
|
0.00
-100.00%
|
74.41
+96630412.99%
|
0.00
|
| Common Stock |
|
0.00
+2136.09%
|
0.00
+72.73%
|
0.00
|
| Preferred Stock |
|
0.00
-100.00%
|
74.41
|
0.00
|
| Share Issued |
|
29.75
+2120.41%
|
1.34
+72.22%
|
0.78
|
| Ordinary Shares Number |
|
29.74
+2132.70%
|
1.33
+72.94%
|
0.77
|
| Treasury Shares Number |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Additional Paid In Capital |
|
183.86
+170.95%
|
67.86
+3.48%
|
65.58
|
| Retained Earnings |
|
-108.08
-46.41%
|
-73.82
-20.09%
|
-61.47
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.59
+84.80%
|
-3.86
|
0.00
|
| Treasury Stock |
|
0.30
+0.00%
|
0.30
+0.00%
|
0.30
|
| Other Equity Adjustments |
|
-0.59
+84.80%
|
-3.86
|
—
|
| Total Equity Gross Minority Interest |
|
74.90
+16.51%
|
64.28
+1588.54%
|
3.81
|
| Total Capitalization |
|
74.90
-5.98%
|
79.66
+1992.57%
|
3.81
|
| Working Capital |
|
5.37
-59.81%
|
13.37
+251.16%
|
3.81
|
| Invested Capital |
|
74.90
+1324.78%
|
5.26
+38.08%
|
3.81
|
| Total Debt |
|
0.16
-98.96%
|
15.59
|
0.00
|
| Net Debt |
|
—
|
0.53
|
—
|
| Capital Lease Obligations |
|
0.16
-20.52%
|
0.20
|
0.00
|
| Net Tangible Assets |
|
-6.49
+50.99%
|
-13.24
-447.84%
|
3.81
|
| Tangible Book Value |
|
-6.49
+92.60%
|
-87.65
-2402.33%
|
3.81
|
| Interest Payable |
|
0.19
-54.95%
|
0.42
+121.99%
|
0.19
|
| Preferred Stock Equity |
|
—
|
74.41
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-15.62
-77.67%
|
-8.79
-80.49%
|
-4.87
+57.53%
|
-11.47
|
| Cash Flow From Continuing Operating Activities |
|
-15.62
-77.67%
|
-8.79
-80.49%
|
-4.87
+57.53%
|
-11.47
|
| Net Income From Continuing Operations |
|
-34.26
-177.39%
|
-12.35
-133.19%
|
-5.30
+56.76%
|
-12.25
|
| Depreciation Amortization Depletion |
|
0.00
-83.06%
|
0.01
|
0.00
|
—
|
| Depreciation |
|
0.00
-83.06%
|
0.01
|
0.00
|
—
|
| Depreciation And Amortization |
|
0.00
-83.06%
|
0.01
|
0.00
|
—
|
| Other Non Cash Items |
|
18.16
+401.48%
|
3.62
|
—
|
—
|
| Stock Based Compensation |
|
0.36
-25.29%
|
0.48
-23.22%
|
0.62
+6.40%
|
0.58
|
| Provisionand Write Offof Assets |
|
—
|
—
|
—
|
—
|
| Deferred Tax |
|
0.22
+44055.47%
|
-0.00
|
0.00
|
—
|
| Deferred Income Tax |
|
0.22
+44055.47%
|
-0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
0.03
-0.45%
|
0.03
|
—
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
0.03
-9.33%
|
0.03
|
0.00
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-0.13
+77.12%
|
-0.58
-198.94%
|
-0.19
-198.51%
|
0.20
|
| Change In Prepaid Assets |
|
-0.21
+58.16%
|
-0.50
-201.72%
|
0.49
+14.09%
|
0.43
|
| Change In Payables And Accrued Expense |
|
0.08
+191.68%
|
-0.08
+87.94%
|
-0.68
-194.68%
|
-0.23
|
| Change In Accrued Expense |
|
0.61
+301.13%
|
-0.30
-35.34%
|
-0.22
+50.52%
|
-0.45
|
| Change In Payable |
|
-0.53
-342.22%
|
0.22
+147.67%
|
-0.46
-310.33%
|
0.22
|
| Change In Account Payable |
|
-0.53
-342.22%
|
0.22
+147.67%
|
-0.46
-310.33%
|
0.22
|
| Investing Cash Flow |
|
0.00
-100.00%
|
3.76
|
0.00
|
—
|
| Cash Flow From Continuing Investing Activities |
|
0.00
-100.00%
|
3.76
|
0.00
|
—
|
| Net Business Purchase And Sale |
|
0.00
-100.00%
|
3.76
|
0.00
|
—
|
| Financing Cash Flow |
|
7.28
-56.39%
|
16.70
+1344.47%
|
1.16
-74.25%
|
4.49
|
| Cash Flow From Continuing Financing Activities |
|
7.28
-56.39%
|
16.70
+1344.47%
|
1.16
-74.25%
|
4.49
|
| Net Issuance Payments Of Debt |
|
3.00
-80.42%
|
15.32
|
0.00
|
—
|
| Issuance Of Debt |
|
3.00
-80.42%
|
15.32
|
0.00
|
—
|
| Long Term Debt Issuance |
|
3.00
-80.42%
|
15.32
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
3.00
-80.42%
|
15.32
|
0.00
|
—
|
| Net Common Stock Issuance |
|
4.34
+213.98%
|
1.38
+19.49%
|
1.16
-74.25%
|
4.49
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.00
|
0.00
|
—
|
| Cash Dividends Paid |
|
—
|
—
|
—
|
—
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
0.00
|
| Net Other Financing Charges |
|
-0.05
|
—
|
—
|
—
|
| Changes In Cash |
|
-8.33
-171.38%
|
11.68
+414.36%
|
-3.71
+46.77%
|
-6.98
|
| Effect Of Exchange Rate Changes |
|
0.01
+107.36%
|
-0.14
|
0.00
|
—
|
| Beginning Cash Position |
|
14.85
+347.64%
|
3.32
-52.82%
|
7.03
-49.81%
|
14.01
|
| End Cash Position |
|
6.52
-56.06%
|
14.85
+347.64%
|
3.32
-52.82%
|
7.03
|
| Free Cash Flow |
|
-15.62
-77.67%
|
-8.79
-80.49%
|
-4.87
+57.53%
|
-11.47
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
4.34
+213.90%
|
1.38
+19.52%
|
1.16
-74.25%
|
4.49
|
| Interest Paid CFF |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
4.34
+213.90%
|
1.38
+19.52%
|
1.16
-74.25%
|
4.49
|
| Sale Of Business |
|
0.00
-100.00%
|
3.76
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-26 View
- 10-K2026-03-18 View
- 8-K2026-03-18 View
- 8-K2026-03-12 View
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-06 View
- 8-K2026-01-20 View
- 8-K2026-01-13 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-12-05 View
- 8-K2025-11-28 View
- 42025-11-25 View
- 8-K2025-11-21 View
- 10-Q2025-11-07 View
- 8-K2025-11-06 View
- 8-K2025-10-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|